{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:33Z","timestamp":1792611693381,"version":"4.5.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/nrneurol.2014.141","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T04:14:01Z","timestamp":1407816841000},"page":"493-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":245,"title":["Treatment of neuromyelitis optica: state-of-the-art and emerging therapies"],"prefix":"10.1038","volume":"10","author":[{"given":"Marios C.","family":"Papadopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,12]]},"reference":[{"key":"BFnrneurol2014141_CR1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon, V. A.  et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106\u20132112 (2004).","journal-title":"Lancet"},{"key":"BFnrneurol2014141_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473\u2013477 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2014141_CR3","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"SR Hinson","year":"2007","unstructured":"Hinson, S. R.  et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69, 2221\u20132231 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F. & Weinshenker, B. G. Revised diagnostic criteria for neuromyelitis optica. Neurology 66, 1485\u20131489 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.56.4.507","volume":"56","author":"P Cabre","year":"2001","unstructured":"Cabre, P.  et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 56, 507\u2013514 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","volume":"256","author":"JA Cabrera-Gomez","year":"2009","unstructured":"Cabrera-Gomez, J. A., Kurtzke, J. F., Gonzalez-Quevedo, A. & Lara-Rodriguez, R. An epidemiological study of neuromyelitis optica in Cuba. J. Neurol. 256, 35\u201344 (2009).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014141_CR7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","volume":"76","author":"N Asgari","year":"2011","unstructured":"Asgari, N.  et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 76, 1589\u20131595 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","volume":"70","author":"B Banwell","year":"2008","unstructured":"Banwell, B.  et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 70, 344\u2013352 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","volume":"82","author":"A Nagaishi","year":"2011","unstructured":"Nagaishi, A.  et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J. Neurol. Neurosurg. Psychiatry 82, 1360\u20131364 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014141_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius, S.  et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J. Neuroinflammation 9, 14 (2012).","journal-title":"J. Neuroinflammation"},{"key":"BFnrneurol2014141_CR11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","volume":"84","author":"A Jacob","year":"2013","unstructured":"Jacob, A.  et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J. Neurol. Neurosurg. Psychiatry 84, 922\u2013930 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014141_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos, M. C. & Verkman, A. S. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 11, 535\u2013544 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014141_CR13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","volume":"47","author":"A Iyer","year":"2014","unstructured":"Iyer, A., Elsone, L., Appleton, R. & Jacob, A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 47, 154\u2013161 (2014).","journal-title":"Autoimmunity"},{"key":"BFnrneurol2014141_CR14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1212\/WNL.0b013e31822f045b","volume":"77","author":"M Matiello","year":"2011","unstructured":"Matiello, M.  et al. Genetic analysis of aquaporin-4 in neuromyelitis optica. Neurology 77, 1149\u20131155 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1399-0039.2008.01172.x","volume":"73","author":"T Matsushita","year":"2009","unstructured":"Matsushita, T.  et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 73, 171\u2013176 (2009).","journal-title":"Tissue Antigens"},{"key":"BFnrneurol2014141_CR16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1352458509350741","volume":"16","author":"DG Brum","year":"2010","unstructured":"Brum, D. G.  et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult. Scler. 16, 21\u201329 (2010).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1352458510382810","volume":"17","author":"R Deschamps","year":"2011","unstructured":"Deschamps, R.  et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult. Scler. 17, 24\u201331 (2011).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1352458508102085","volume":"15","author":"H Zephir","year":"2009","unstructured":"Zephir, H.  et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult. Scler. 15, 571\u2013579 (2009).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/WNL.0b013e3181ea9f15","volume":"75","author":"M Matiello","year":"2010","unstructured":"Matiello, M.  et al. Familial neuromyelitis optica. Neurology 75, 310\u2013315 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/brain\/awm027","volume":"130","author":"T Matsuoka","year":"2007","unstructured":"Matsuoka, T.  et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130, 1206\u20131223 (2007).","journal-title":"Brain"},{"key":"BFnrneurol2014141_CR21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jnnp.2005.080390","volume":"77","author":"I Nakashima","year":"2006","unstructured":"Nakashima, I.  et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J. Neurol. Neurosurg. Psychiatry 77, 1073\u20131075 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014141_CR22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/jnnp.2007.131177","volume":"79","author":"JS Wu","year":"2008","unstructured":"Wu, J. S., Zhang, M. N., Carroll, W. M. & Kermode, A. G. Characterisation of the spectrum of demyelinating disease in Western Australia. J. Neurol. Neurosurg. Psychiatry 79, 1022\u20131026 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014141_CR23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.0000000000000114","volume":"82","author":"BG Weinshenker","year":"2014","unstructured":"Weinshenker, B. G. & Wingerchuk, D. M. The two faces of neuromyelitis optica. Neurology 82, 466\u2013467 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius, S. & Wildemann, B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 6, 383\u2013392 (2010).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol2014141_CR25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","volume":"4","author":"S Jarius","year":"2008","unstructured":"Jarius, S.  et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol. 4, 202\u2013214 (2008).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"BFnrneurol2014141_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","volume":"72","author":"M Varrin-Doyer","year":"2012","unstructured":"Varrin-Doyer, M.  et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann. Neurol. 72, 53\u201364 (2012).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014141_CR27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jns.2010.10.013","volume":"300","author":"M Koga","year":"2011","unstructured":"Koga, M., Takahashi, T., Kawai, M., Fujihara, K. & Kanda, T. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J. Neurol. Sci. 300, 19\u201322 (2011).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014141_CR28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","volume":"83","author":"F Shimizu","year":"2012","unstructured":"Shimizu, F.  et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J. Neurol. Neurosurg. Psychiatry 83, 288\u2013297 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014141_CR29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","volume":"7","author":"S Jarius","year":"2010","unstructured":"Jarius, S.  et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J. Neuroinflammation 7, 52 (2010).","journal-title":"J. Neuroinflammation"},{"key":"BFnrneurol2014141_CR30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/archneurol.2010.269","volume":"67","author":"SR Kalluri","year":"2010","unstructured":"Kalluri, S. R.  et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch. Neurol. 67, 1201\u20131208 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR31","doi-asserted-by":"crossref","first-page":"e83036","DOI":"10.1371\/journal.pone.0083036","volume":"8","author":"N Chihara","year":"2013","unstructured":"Chihara, N.  et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS ONE 8, e83036 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2014141_CR32","first-page":"75","volume":"15","author":"M Bradl","year":"2008","unstructured":"Bradl, M. & Lassmann, D. H. Anti-aquaporin-4 antibodies in neuromyelitis optica: how to prove their pathogenetic relevance? Int. MS J. 15, 75\u201378 (2008).","journal-title":"Int. MS J."},{"key":"BFnrneurol2014141_CR33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun, S.  et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G. and human complement produces neuromyelitis optica lesions in mice. Brain 133, 349\u2013361 (2010).","journal-title":"Brain"},{"key":"BFnrneurol2014141_CR34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett, J. L.  et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 66, 617\u2013629 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014141_CR35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","volume":"70","author":"H Zhang","year":"2011","unstructured":"Zhang, H., Bennett, J. L. & Verkman, A. S. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann. Neurol. 70, 943\u2013954 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014141_CR36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","volume":"123","author":"J Ratelade","year":"2012","unstructured":"Ratelade, J.  et al. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol. 123, 861\u2013872 (2012).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2014141_CR37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","volume":"71","author":"S Saadoun","year":"2012","unstructured":"Saadoun, S.  et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann. Neurol. 71, 323\u2013333 (2012).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014141_CR38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","volume":"126","author":"J Ratelade","year":"2013","unstructured":"Ratelade, J.  et al. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. 126, 699\u2013709 (2013).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2014141_CR39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00401-013-1220-8","volume":"127","author":"C Wrzos","year":"2014","unstructured":"Wrzos, C.  et al. Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol. 127, 523\u2013538 (2014).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2014141_CR40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/2051-5960-1-85","volume":"1","author":"M Pohl","year":"2013","unstructured":"Pohl, M.  et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol. Commun. 1, 85 (2013).","journal-title":"Acta Neuropathol. Commun."},{"key":"BFnrneurol2014141_CR41","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/WNR.0b013e32835ab480","volume":"23","author":"S Saadoun","year":"2012","unstructured":"Saadoun, S., Bridges, L. R., Verkman, A. S. & Papadopoulos, M. C. Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions. Neuroreport 23, 1044\u20131047 (2012).","journal-title":"Neuroreport"},{"key":"BFnrneurol2014141_CR42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jneuroim.2011.03.007","volume":"235","author":"S Saadoun","year":"2011","unstructured":"Saadoun, S.  et al. T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. J. Neuroimmunol. 235, 27\u201332 (2011).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014141_CR43","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson, S. R.  et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 205, 2473\u20132481 (2008).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2014141_CR44","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","volume":"109","author":"SR Hinson","year":"2012","unstructured":"Hinson, S. R.  et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc. Natl Acad. Sci. USA 109, 1245\u20131250 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2014141_CR45","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/glia.22417","volume":"60","author":"A Rossi","year":"2012","unstructured":"Rossi, A., Ratelade, J., Papadopoulos, M. C., Bennett, J. L. & Verkman, A. S. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1\/M23 isoform content, or supramolecular assembly. Glia 60, 2027\u20132039 (2012).","journal-title":"Glia"},{"key":"BFnrneurol2014141_CR46","doi-asserted-by":"crossref","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","volume":"286","author":"J Ratelade","year":"2011","unstructured":"Ratelade, J., Bennett, J. L. & Verkman, A. S. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J. Biol. Chem. 286, 45156\u201345164 (2011).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2014141_CR47","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1523\/JNEUROSCI.3547-03.2004","volume":"24","author":"JR Faulkner","year":"2004","unstructured":"Faulkner, J. R.  et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24, 2143\u20132155 (2004).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2014141_CR48","doi-asserted-by":"crossref","first-page":"11511","DOI":"10.1523\/JNEUROSCI.1514-09.2009","volume":"29","author":"RR Voskuhl","year":"2009","unstructured":"Voskuhl, R. R.  et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J. Neurosci. 29, 11511\u201311522 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2014141_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst, C.  et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J. Neurol. 261, 1\u201316 (2014).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014141_CR50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough, D. J.  et al. Treatment of neuromyelitis optica: review and recommendations. Mult. Scler. Relat. Disord. 1, 180\u2013187 (2012).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"BFnrneurol2014141_CR51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk, D. M., Pittock, S. J., Lucchinetti, C. F., Lennon, V. A. & Weinshenker, B. G. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68, 603\u2013605 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejphar.2005.12.052","volume":"533","author":"PJ Barnes","year":"2006","unstructured":"Barnes, P. J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533, 2\u201314 (2006).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrneurol2014141_CR53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","volume":"33","author":"UC Linhares","year":"2013","unstructured":"Linhares, U. C.  et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J. Clin. Immunol. 33, 179\u2013189 (2013).","journal-title":"J. Clin. Immunol."},{"key":"BFnrneurol2014141_CR54","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jocn.2011.01.031","volume":"18","author":"HH Wang","year":"2011","unstructured":"Wang, H. H.  et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 18, 1313\u20131317 (2011).","journal-title":"J. Clin. Neurosci."},{"key":"BFnrneurol2014141_CR55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2011.12.010","volume":"243","author":"N Muls","year":"2012","unstructured":"Muls, N.  et al. Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J. Neuroimmunol. 243, 73\u201380 (2012).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014141_CR56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","volume":"164","author":"HM Reeves","year":"2014","unstructured":"Reeves, H. M. & Winters, J. L. The mechanisms of action of plasma exchange. Br. J. Haematol. 164, 342\u2013351 (2014).","journal-title":"Br. J. Haematol."},{"key":"BFnrneurol2014141_CR57","first-page":"787630","volume":"2012","author":"M Bonnan","year":"2012","unstructured":"Bonnan, M. & Cabre, P. Plasma exchange in severe attacks of neuromyelitis optica. Mult. Scler. Int. 2012, 787630 (2012).","journal-title":"Mult. Scler. Int."},{"key":"BFnrneurol2014141_CR58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","volume":"15","author":"M Bonnan","year":"2009","unstructured":"Bonnan, M.  et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult. Scler. 15, 487\u2013492 (2009).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","volume":"58","author":"M Keegan","year":"2002","unstructured":"Keegan, M.  et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58, 143\u2013146 (2002).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR60","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle, H.  et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch. Ophthalmol. 130, 858\u2013862 (2012).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrneurol2014141_CR61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone, L.  et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult. Scler. 20, 501\u2013504 (2014).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR62","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1212\/01.wnl.0000260970.63493.c8","volume":"68","author":"BM Greenberg","year":"2007","unstructured":"Greenberg, B. M.  et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 68, 1614\u20131617 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR63","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley, J.  et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135, 1834\u20131849 (2012).","journal-title":"Brain"},{"key":"BFnrneurol2014141_CR64","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe, S.  et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult. Scler. 13, 968\u2013974 (2007).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1744-9987.2009.00780.x","volume":"13","author":"K Miyamoto","year":"2009","unstructured":"Miyamoto, K. & Kusunoki, S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther. Apher. Dial. 13, 505\u2013508 (2009).","journal-title":"Ther. Apher. Dial."},{"key":"BFnrneurol2014141_CR66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi, C.  et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77, 659\u2013666 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR67","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","volume":"67","author":"DB Bichuetti","year":"2010","unstructured":"Bichuetti, D. B., Lobato de Oliveira, E. M., Oliveira, D. M., Amorin de Souza, N. & Gabbai, A. A. Neuromyelitis optica treatment: analysis of 36 patients. Arch. Neurol. 67, 1131\u20131136 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR68","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1468-1331.2009.02928.x","volume":"17","author":"MA Sahraian","year":"2010","unstructured":"Sahraian, M. A., Moinfar, Z., Khorramnia, S. & Ebrahim, M. M. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur. J. Neurol. 17, 794\u2013799 (2010).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol2014141_CR69","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob, A.  et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch. Neurol. 66, 1128\u20131133 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR70","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","volume":"84","author":"J Kitley","year":"2013","unstructured":"Kitley, J.  et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J. Neurol. Neurosurg. Psychiatry 84, 918\u2013921 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014141_CR71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","volume":"68","author":"S-H Kim","year":"2010","unstructured":"Kim, S.-H.  et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch. Neurol. 68, 473\u2013479 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR72","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2169\/internalmedicine.52.7885","volume":"52","author":"H Yaguchi","year":"2013","unstructured":"Yaguchi, H.  et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern. Med. 52, 969\u2013972 (2013).","journal-title":"Intern. Med."},{"key":"BFnrneurol2014141_CR73","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneurol.2012.545","volume":"69","author":"DB Bichuetti","year":"2012","unstructured":"Bichuetti, D. B., Oliveira, E. M., Boulos Fde, C. & Gabbai, A. A. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch. Neurol. 69, 938\u2013939 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR74","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree, B. A.  et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270\u20131272 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR75","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob, A.  et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65, 1443\u20131448 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR76","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"S-H Kim","year":"2011","unstructured":"Kim, S.-H., Kim, W., Li, X. F., Jung, I.-J. & Kim, H. J. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol. 68, 1412\u20131420 (2011).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR77","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi, G. S.  et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult. Scler. 17, 1225\u20131230 (2011).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR78","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"S-H Kim","year":"2013","unstructured":"Kim, S.-H., Huh, S.-Y., Lee, S. J., Joung, A. & Kim, H. J. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 70, 1110\u20131117 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2014141_CR79","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","volume":"18","author":"BM Greenberg","year":"2012","unstructured":"Greenberg, B. M.  et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult. Scler. 18, 1022\u20131026 (2012).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR80","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius, S.  et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131, 3072\u20133080 (2008).","journal-title":"Brain"},{"key":"BFnrneurol2014141_CR81","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer, H. L.  et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76, 1310\u20131315 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR82","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim, S. H., Huh, S. Y., Lee, S. J., Joung, A. & Kim, H. J. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 70, 1110\u20131117 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2014141_CR83","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson, K. R.  et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10, 816\u2013824 (2009).","journal-title":"Lancet Oncol."},{"key":"BFnrneurol2014141_CR84","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","volume":"260","author":"T Kageyama","year":"2013","unstructured":"Kageyama, T.  et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J. Neurol. 260, 627\u2013634 (2013).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014141_CR85","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1212\/WNL.0b013e31824c466f","volume":"78","author":"B Bourre","year":"2012","unstructured":"Bourre, B.  et al. Neuromyelitis optica and pregnancy. Neurology 78, 875\u2013879 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR86","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","volume":"78","author":"W Kim","year":"2012","unstructured":"Kim, W.  et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78, 1264\u20131267 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR87","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1177\/1352458513498125","volume":"19","author":"M Ringelstein","year":"2013","unstructured":"Ringelstein, M.  et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult. Scler. 19, 1544\u20131547 (2013).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR88","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1460-9568.1999.00502.x","volume":"11","author":"H Wen","year":"1999","unstructured":"Wen, H.  et al. Ontogeny of water transport in rat brain: postnatal expression of the aquaporin-4 water channel. Eur. J. Neurosci. 11, 935\u2013945 (1999).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrneurol2014141_CR89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijdevneu.2006.05.003","volume":"24","author":"E Gomori","year":"2006","unstructured":"Gomori, E.  et al. Fetal development of membrane water channel proteins aquaporin-1 and aquaporin-4 in the human brain. Int. J. Dev. Neurosci. 24, 295\u2013305 (2006).","journal-title":"Int. J. Dev. Neurosci."},{"key":"BFnrneurol2014141_CR90","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.4049\/jimmunol.1301483","volume":"191","author":"S Saadoun","year":"2013","unstructured":"Saadoun, S.  et al. Neuromyelitis optica IgG causes placental inflammation and fetal death. J. Immunol. 191, 2999\u20133005 (2013).","journal-title":"J. Immunol."},{"issue":"Suppl. 2","key":"BFnrneurol2014141_CR91","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.placenta.2010.12.012","volume":"32","author":"AE Damiano","year":"2011","unstructured":"Damiano, A. E. Review: water channel proteins in the human placenta and fetal membranes. Placenta 32 (Suppl. 2), S207\u2013S211 (2011).","journal-title":"Placenta"},{"key":"BFnrneurol2014141_CR92","first-page":"813","volume":"21","author":"M De Falco","year":"2007","unstructured":"De Falco, M.  et al. Down-regulation of aquaporin 4 in human placenta throughout pregnancy. In Vivo 21, 813\u2013817 (2007).","journal-title":"In Vivo"},{"key":"BFnrneurol2014141_CR93","doi-asserted-by":"crossref","first-page":"b4026","DOI":"10.1136\/bmj.b4026","volume":"339","author":"R Reuss","year":"2009","unstructured":"Reuss, R.  et al. A woman with acute myelopathy in pregnancy: case outcome. BMJ 339, b4026 (2009).","journal-title":"BMJ"},{"key":"BFnrneurol2014141_CR94","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s00415-013-7031-y","volume":"260","author":"YD Fragoso","year":"2013","unstructured":"Fragoso, Y. D.  et al. Neuromyelitis optica and pregnancy. J. Neurol. 260, 2614\u20132619 (2013).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014141_CR95","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/1352458509106512","volume":"15","author":"HL Pellkofer","year":"2009","unstructured":"Pellkofer, H. L., Suessmair, C., Schulze, A., Hohlfeld, R. & Kuempfel, T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult. Scler. 15, 1006\u20131008 (2009).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR96","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/0883073807306270","volume":"22","author":"D Yuksel","year":"2007","unstructured":"Yuksel, D., Senbil, N., Yilmaz, D. & Yavuz Gurer, Y. K. Devic's neuromyelitis optica in an infant case. J. Child. Neurol. 22, 1143\u20131146 (2007).","journal-title":"J. Child. Neurol."},{"key":"BFnrneurol2014141_CR97","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/0883073812451495","volume":"27","author":"JM Tillema","year":"2012","unstructured":"Tillema, J. M. & McKeon, A. The spectrum of neuromyelitis optica (NMO) in childhood. J. Child. Neurol. 27, 1437\u20131447 (2012).","journal-title":"J. Child. Neurol."},{"key":"BFnrneurol2014141_CR98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","volume":"71","author":"A McKeon","year":"2008","unstructured":"McKeon, A.  et al. CNS aquaporin-4 autoimmunity in children. Neurology 71, 93\u2013100 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR99","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1542\/peds.2007-2758","volume":"122","author":"TE Lotze","year":"2008","unstructured":"Lotze, T. E.  et al. Spectrum of pediatric neuromyelitis optica. Pediatrics 122, e1039\u2013e1047 (2008).","journal-title":"Pediatrics"},{"key":"BFnrneurol2014141_CR100","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1212\/WNL.0b013e3181fc2823","volume":"75","author":"P Huppke","year":"2010","unstructured":"Huppke, P.  et al. Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology 75, 1740\u20131804 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR101","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","volume":"18","author":"S-H Kim","year":"2012","unstructured":"Kim, S.-H., Kim, W., Li, X. F., Jung, I.-J. & Kim, H. J. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult. Scler. 18, 1480\u20131483 (2012).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR102","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","volume":"67","author":"J Palace","year":"2010","unstructured":"Palace, J., Leite, M. I., Nairne, A. & Vincent, A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 67, 1016\u20131017 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR103","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","volume":"75","author":"J Shimizu","year":"2010","unstructured":"Shimizu, J.  et al. IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75, 1423\u20131427 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","volume":"252","author":"Y Warabi","year":"2007","unstructured":"Warabi, Y., Matsumoto, Y. & Hayashi, H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci. 252, 57\u201361 (2007).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014141_CR105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-011-8296-5","volume":"44","author":"RC Axtell","year":"2012","unstructured":"Axtell, R. C., Raman, C. & Steinman, L. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin. Rev. Allergy Immunol. 44, 114\u2013120 (2012).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"BFnrneurol2014141_CR106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter, I.  et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch. Neurol. 69, 239\u2013245 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR107","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","volume":"18","author":"M Barnett","year":"2012","unstructured":"Barnett, M., Prineas, J., Buckland, M., Parratt, J. & Pollard, J. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult. Scler. 18, 108\u2013112 (2012).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jns.2014.01.035","volume":"339","author":"J Kitley","year":"2014","unstructured":"Kitley, J.  et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J. Neurol. Sci. 339, 223\u2013225 (2014).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014141_CR109","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter, I.  et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch. Neurol. 69, 239\u2013245 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman, C. H.  et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899\u2013910 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014141_CR111","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti, C. F.  et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125, 1450\u20131461 (2002).","journal-title":"Brain"},{"key":"BFnrneurol2014141_CR112","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","volume":"123","author":"H Zhang","year":"2013","unstructured":"Zhang, H. & Verkman, A. S. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J. Clin. Invest. 123, 2306\u20132316 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2014141_CR113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ni.1981","volume":"12","author":"VT Chu","year":"2011","unstructured":"Chu, V. T.  et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat. Immunol. 12, 151\u2013159 (2011).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol2014141_CR114","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","volume":"18","author":"JH Min","year":"2012","unstructured":"Min, J. H., Kim, B. J. & Lee, K. H. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult. Scler. 18, 113\u2013115 (2012).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.5692\/clinicalneurol.53.513","volume":"53","author":"S Izaki","year":"2013","unstructured":"Izaki, S.  et al. A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment [Japanese]. Rinsho Shinkeigaku 53, 513\u2013517 (2013).","journal-title":"Rinsho Shinkeigaku"},{"key":"BFnrneurol2014141_CR116","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2353\/ajpath.2010.100119","volume":"177","author":"K Sugita","year":"2010","unstructured":"Sugita, K.  et al. FTY720 regulates bone marrow egress of eosinophils and modulates late-phase skin reaction in mice. Am. J. Pathol. 177, 1881\u20131887 (2010).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2014141_CR117","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock, S. J.  et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 12, 554\u2013562 (2013).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014141_CR118","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara, N.  et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc. Natl Acad. Sci. USA 108, 3701\u20133706 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2014141_CR119","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","volume":"421","author":"A Uzawa","year":"2013","unstructured":"Uzawa, A.  et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin. Chim. Acta 421, 181\u2013183 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrneurol2014141_CR120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","volume":"19","author":"H Wang","year":"2012","unstructured":"Wang, H.  et al. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 19, 304\u2013308 (2012).","journal-title":"Neuroimmunomodulation"},{"key":"BFnrneurol2014141_CR121","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","volume":"23","author":"M Araki","year":"2013","unstructured":"Araki, M.  et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod. Rheumatol 23, 827\u2013831 (2013).","journal-title":"Mod. Rheumatol"},{"key":"BFnrneurol2014141_CR122","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg, I.  et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 70, 394\u2013397 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2014141_CR123","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","volume":"70","author":"BC Kieseier","year":"2013","unstructured":"Kieseier, B. C.  et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 70, 390\u2013393 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2014141_CR124","doi-asserted-by":"publisher","unstructured":"Komai, T.  et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report. Mod. Rheumatol http:\/\/dx.doi.org\/10.3109\/14397595.2013.861333.","DOI":"10.3109\/14397595.2013.861333"},{"key":"BFnrneurol2014141_CR125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-013-1204-8","volume":"127","author":"N Asavapanumas","year":"2014","unstructured":"Asavapanumas, N., Ratelade, J. & Verkman, A. S. Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG. Acta Neuropathol. 127, 539\u2013551 (2014).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2014141_CR126","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius, S.  et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J. Neurol. Sci. 306, 82\u201390 (2011).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014141_CR127","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1177\/1352458512443994","volume":"18","author":"A Jacob","year":"2012","unstructured":"Jacob, A.  et al. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. Mult. Scler. 18, 1801\u20131803 (2012).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR128","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.4049\/jimmunol.172.7.4493","volume":"172","author":"RE Young","year":"2004","unstructured":"Young, R. E.  et al. Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE in neutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles in vivo. J. Immunol. 172, 4493\u20134502 (2004).","journal-title":"J. Immunol."},{"key":"BFnrneurol2014141_CR129","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1083\/jcb.201006052","volume":"191","author":"V Papayannopoulos","year":"2010","unstructured":"Papayannopoulos, V., Metzler, K. D., Hakkim, A. & Zychlinsky, A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J. Cell Biol. 191, 677\u2013691 (2010).","journal-title":"J. Cell Biol."},{"key":"BFnrneurol2014141_CR130","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.2169\/internalmedicine.49.4010","volume":"49","author":"K Iwata","year":"2010","unstructured":"Iwata, K.  et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern. Med. 49, 2423\u20132432 (2010).","journal-title":"Intern. Med."},{"key":"BFnrneurol2014141_CR131","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0006-291X(91)91862-7","volume":"177","author":"K Kawabata","year":"1991","unstructured":"Kawabata, K.  et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. 177, 814\u2013820 (1991).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneurol2014141_CR132","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-065X.2011.01026.x","volume":"242","author":"H Kita","year":"2011","unstructured":"Kita, H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol. Rev. 242, 161\u2013177 (2011).","journal-title":"Immunol. Rev."},{"key":"BFnrneurol2014141_CR133","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach, P.  et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1, 1228\u20131231 (1981).","journal-title":"Lancet"},{"key":"BFnrneurol2014141_CR134","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","volume":"367","author":"EW Gelfand","year":"2012","unstructured":"Gelfand, E. W. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 367, 2015\u20132025 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014141_CR135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","volume":"7","author":"S Jacob","year":"2009","unstructured":"Jacob, S. & Rajabally, Y. A. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr. Neuropharmacol. 7, 337\u2013342 (2009).","journal-title":"Curr. Neuropharmacol."},{"key":"BFnrneurol2014141_CR136","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","volume":"28","author":"MJ Magraner","year":"2013","unstructured":"Magraner, M. J., Coret, F. & Casanova, B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 28, 65\u201372 (2013).","journal-title":"Neurologia"},{"key":"BFnrneurol2014141_CR137","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"J Bakker","year":"2004","unstructured":"Bakker, J. & Metz, L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can. J. Neurol. Sci. 31, 265\u2013267 (2004).","journal-title":"Can. J. Neurol. Sci."},{"key":"BFnrneurol2014141_CR138","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","volume":"46","author":"K Okada","year":"2007","unstructured":"Okada, K., Tsuji, S. & Tanaka, K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern. Med. 46, 1671\u20131672 (2007).","journal-title":"Intern. Med."},{"key":"BFnrneurol2014141_CR139","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.expneurol.2014.03.004","volume":"255","author":"J Ratelade","year":"2014","unstructured":"Ratelade, J., Smith, A. J. & Verkman, A. S. Intravenous immunoglobulin (IVIg) reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp. Neurol. 255, 145\u2013153 (2014).","journal-title":"Exp. Neurol."},{"key":"BFnrneurol2014141_CR140","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","volume":"5","author":"TF Tedder","year":"2009","unstructured":"Tedder, T. F. CD19: a promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 572\u2013577 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrneurol2014141_CR141","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","volume":"4","author":"O Hammer","year":"2012","unstructured":"Hammer, O. CD19 as an attractive target for antibody-based therapy. MAbs 4, 571\u2013577 (2012).","journal-title":"MAbs"},{"key":"BFnrneurol2014141_CR142","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1471-4159.2010.07084.x","volume":"116","author":"S Kim","year":"2011","unstructured":"Kim, S., Steelman, A. J., Koito, H. & Li, J. Astrocytes promote TNF-mediated toxicity to oligodendrocyte precursors. J. Neurochem. 116, 53\u201366 (2011).","journal-title":"J. Neurochem."},{"key":"BFnrneurol2014141_CR143","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1476-9255-6-18","volume":"6","author":"G Pent\u00f3n-Rol","year":"2009","unstructured":"Pent\u00f3n-Rol, G.  et al. TNF-\u03b1 and IL-10 downregulation and marked oxidative stress in neuromyelitis optica. J. Inflamm. (Lond.) 6, 18 (2009).","journal-title":"J. Inflamm. (Lond.)"},{"key":"BFnrneurol2014141_CR144","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip, L.  et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann. Neurol. 71, 314\u2013322 (2012).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014141_CR145","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","volume":"26","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip, L.  et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J. 26, 2197\u20132208 (2012).","journal-title":"FASEB J."},{"key":"BFnrneurol2014141_CR146","doi-asserted-by":"crossref","first-page":"36837","DOI":"10.1074\/jbc.M112.408716","volume":"287","author":"PW Phuan","year":"2012","unstructured":"Phuan, P. W.  et al. A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4. J. Biol. Chem. 287, 36837\u201336844 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2014141_CR147","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","volume":"286","author":"JM Crane","year":"2011","unstructured":"Crane, J. M.  et al. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays. J. Biol. Chem. 286, 16516\u201316524 (2011).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2014141_CR148","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","volume":"287","author":"PW Phuan","year":"2012","unstructured":"Phuan, P. W., Ratelade, J., Rossi, A., Tradtrantip, L. & Verkman, A. S. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J. Biol. Chem. 287, 13829\u201313839 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2014141_CR149","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.mehy.2013.10.011","volume":"81","author":"S Jarius","year":"2013","unstructured":"Jarius, S. & Wildemann, B. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link. Med. Hypotheses 81, 1090\u20131095 (2013).","journal-title":"Med. Hypotheses"},{"key":"BFnrneurol2014141_CR150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.mehy.2009.02.036","volume":"73","author":"A Warth","year":"2009","unstructured":"Warth, A. Prevention of orthogonal array of particles formation as a treatment approach for neuromyelitis optica. Med. Hypotheses 73, 361\u2013362 (2009).","journal-title":"Med. Hypotheses"},{"key":"BFnrneurol2014141_CR151","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/emboj\/20.12.3046","volume":"20","author":"M Collin","year":"2001","unstructured":"Collin, M. & Olsen, A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J. 20, 3046\u20133055 (2001).","journal-title":"EMBO J."},{"key":"BFnrneurol2014141_CR152","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ana.23741","volume":"73","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip, L., Ratelade, J., Zhang, H. & Verkman, A. S. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G. into therapeutic antibody. Ann. Neurol. 73, 77\u201385 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014141_CR153","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.113.086470","volume":"83","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip, L., Asavapanumas, N. & Verkman, A. S. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol. Pharmacol. 83, 1268\u20131275 (2013).","journal-title":"Mol. Pharmacol."},{"key":"BFnrneurol2014141_CR154","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/viru.26515","volume":"5","author":"LA Lewis","year":"2014","unstructured":"Lewis, L. A. & Ram, S. Meningococcal disease and the complement system. Virulence 5, 98\u2013126 (2014).","journal-title":"Virulence"},{"key":"BFnrneurol2014141_CR155","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","volume":"125","author":"PW Phuan","year":"2013","unstructured":"Phuan, P. W.  et al. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol. 125, 829\u2013840 (2013).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2014141_CR156","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","volume":"25","author":"D Ricklin","year":"2007","unstructured":"Ricklin, D. & Lambris, J. D. Complement-targeted therapeutics. Nat. Biotechnol. 25, 1265\u20131275 (2007).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2014141_CR157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4614-4118-2_1","volume":"735","author":"D Ricklin","year":"2013","unstructured":"Ricklin, D. & Lambris, J. D. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 735, 1\u201322 (2013).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFnrneurol2014141_CR158","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF02918257","volume":"12","author":"A Davies","year":"1993","unstructured":"Davies, A. & Lachmann, P. J. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol. Res. 12, 258\u2013275 (1993).","journal-title":"Immunol. Res."},{"key":"BFnrneurol2014141_CR159","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel, P. F. & Skerka, C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729\u2013740 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrneurol2014141_CR160","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","volume":"46","author":"M Botto","year":"2009","unstructured":"Botto, M.  et al. Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 46, 2774\u20132783 (2009).","journal-title":"Mol. Immunol."},{"key":"BFnrneurol2014141_CR161","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-2094-11-16","volume":"11","author":"N Asavapanumas","year":"2014","unstructured":"Asavapanumas, N.  et al. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J. Neuroinflammation 11, 16 (2014).","journal-title":"J. Neuroinflammation"},{"key":"BFnrneurol2014141_CR162","doi-asserted-by":"publisher","unstructured":"Zhang, H. & Verkman, A. S. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J. Autoimmun. http:\/\/dx.doi.org\/10.1016\/j.jaut.2014.02.011.","DOI":"10.1016\/j.jaut.2014.02.011"},{"key":"BFnrneurol2014141_CR163","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","volume":"181","author":"T Vincent","year":"2008","unstructured":"Vincent, T.  et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood\u2013brain barrier permeability and granulocyte recruitment. J. Immunol. 181, 5730\u20135737 (2008).","journal-title":"J. Immunol."},{"key":"BFnrneurol2014141_CR164","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.autrev.2012.10.008","volume":"12","author":"S Mihai","year":"2013","unstructured":"Mihai, S. & Nimmerjahn, F. The role of Fc receptors and complement in autoimmunity. Autoimmun. Rev. 12, 657\u2013660 (2013).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneurol2014141_CR165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.04.009","volume":"236","author":"T Hosokawa","year":"2011","unstructured":"Hosokawa, T.  et al. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier. J. Neuroimmunol. 236, 81\u201386 (2011).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014141_CR166","doi-asserted-by":"crossref","unstructured":"Bluestone, J. A. & Bour-Jordan, H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb. Perspect. Biol. 4 (2012).","DOI":"10.1101\/cshperspect.a007542"},{"key":"BFnrneurol2014141_CR167","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","volume":"64","author":"A Bar-Or","year":"2007","unstructured":"Bar-Or, A.  et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial. Arch. Neurol. 64, 1407\u20131415 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR168","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17402520600876804","volume":"13","author":"AMC Faria","year":"2006","unstructured":"Faria, A. M. C. & Weiner, H. L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13, 143\u2013157 (2006).","journal-title":"Clin. Dev. Immunol."},{"key":"BFnrneurol2014141_CR169","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","volume":"6","author":"B Bielekova","year":"2000","unstructured":"Bielekova, B.  et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83\u201399) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6, 1167\u20131175 (2000).","journal-title":"Nat. Med."},{"key":"BFnrneurol2014141_CR170","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1352458508096875","volume":"15","author":"J Fagius","year":"2008","unstructured":"Fagius, J., Lundgren, J. & Oberg, G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult. Scler. 15, 229\u2013237 (2008).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR171","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/ard.2010.148049","volume":"70","author":"GG Illei","year":"2011","unstructured":"Illei, G. G.  et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann. Rheum. Dis. 70, 2071\u20132074 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol2014141_CR172","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader, S.  et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J. Neuroinflammation 8, 184 (2011).","journal-title":"J. Neuroinflammation"},{"key":"BFnrneurol2014141_CR173","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2013.3890","volume":"70","author":"J Kitley","year":"2013","unstructured":"Kitley, J.  et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol. 70, 1375\u20131381 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2014141_CR174","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley, J.  et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 71, 276\u2013283 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2014141_CR175","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley, J.  et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79, 1273\u20131277 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR176","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/1352458512470310","volume":"19","author":"K Rostasy","year":"2013","unstructured":"Rostasy, K.  et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult. Scler. 19, 1052\u20131059 (2013).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014141_CR177","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato, D. K.  et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82, 474\u2013481 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR178","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","volume":"9","author":"M Reindl","year":"2013","unstructured":"Reindl, M., Di Pauli, F., Rostasy, K. & Berger, T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat. Rev. Neurol. 9, 455\u2013461 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol2014141_CR179","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","volume":"2","author":"S Saadoun","year":"2014","unstructured":"Saadoun, S.  et al. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol. Commun. 2, 35 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"BFnrneurol2014141_CR180","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy, M. A., Wingerchuk, D. M., Palace, J., Greenberg, B. M. & Levy, M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 71, 324\u2013330 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2014141_CR181","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer, H. L.  et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76, 1310\u20131315 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014141_CR182","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","volume":"63","author":"B Weinstock-Guttman","year":"2006","unstructured":"Weinstock-Guttman, B.  et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. 63, 957\u2013963 (2006).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014141_CR183","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jneuroim.2011.03.009","volume":"234","author":"Y Li","year":"2011","unstructured":"Li, Y., Wang, H., Long, Y., Lu, Z. & Hu, X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J. Neuroimmunol. 234, 155\u2013160 (2011).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014141_CR184","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.chembiol.2012.12.009","volume":"20","author":"BL Raveendra","year":"2013","unstructured":"Raveendra, B. L.  et al. Discovery of peptoid ligands for anti-aquaporin 4 antibodies. Chem. Biol. 20, 351\u2013359 (2013).","journal-title":"Chem. Biol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.141","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:13:38Z","timestamp":1684455218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2014.141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,12]]},"references-count":184,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFnrneurol2014141"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2014.141","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,12]]},"assertion":[{"value":"12 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.C.P. has received consulting income from ONO Pharmaceutical. J.L.B. has received consulting income from MedImmune and Chugai Pharmaceuticals. He has a patent application on aquaporumab technology and is a member of the board of directors of Apsara Therapeutics. A.S.V. has patent applications on aquaporumab and EndoS technology and is a member of the board of directors of Apsara Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}